Two de novo go-aheads granted by FDA last month sent non-implantable neurostimulation devices to market, one for headaches and the other for tear production. Overall, the agency granted four de novos in April, continuing a strong trend this year for that marketing pathway, according to Medtech Insight's Approvals Tracker.
[Editors' note: For sortable and searchable tables of US and international approvals and clearances check out our Approvals Tracker.]
R&D into non-invasive neurostimulation devices, a market attracting serious attention and investment from both drug and device firms, showed signs...